Obesity biotech Kailera Therapeutics sets terms for $500 million IPO
April 17, 2026 News
Obesity biotech Kailera Therapeutics prices upsized IPO at $16 high end
Kailera Therapeutics, a phase 3 biotech developing injectable and oral GLP-1 agonists for obesity, raised $625 million by offering 39.1 million shares at $16, the high end of the $14 to $16 range. The company originally planned to offer 33.3 million shares at the same range. Existing shareholders Bain Capital and QIA ahd indicated on $225mm of the deal. At pricing, the company commands a fully diluted market value of $2.1 billion （+12% vs. original midpoint）。
IPO Overview
Kailera Therapeutics, a Phase 3 biotech developing injectable and oral GLP-1s for obesity, announced terms for its IPO on Monday.
The Waltham, MA-based company plans to raise $500 million by offering 33.3 million shares at a price range of $14 to $16. Certain shareholders intend to purchase $225 million worth of shares in the offering （45% of the deal）。
Kailera is progressing four clinical-stage candidates targeting obesity, leveraging multiple glucagon-like peptide-1 （GLP-1） based mechanisms of action and routes of administration. Its lead candidate, ribupatide （also known as KAI-9531）， is currently being evaluated in global Phase 3 trials as a once-weekly injectable GLP-1/glucose-dependent insulinotropic polypeptide receptor dual agonist peptide. The company is expanding its ribupatide franchise by developing a once-daily oral tablet formulation, oral ribupatide, based on the same peptide as injectable ribupatide.
Kailera Therapeutics was founded in 2024. It plans to list on the Nasdaq under the symbol KLRA. J.P. Morgan, Jefferies, Leerink Partners, TD Securities, and Evercore ISI are the joint bookrunners on the deal. It is expected to price this week.
About the Company
We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. We are rapidly progressing four clinical-stage product candidates, leveraging multiple glucagon-like peptide-1, or GLP-1, based mechanisms of action and routes of administration. Our lead product candidate, ribupatide （also known as KAI-9531）， is currently being evaluated in global Phase 3 trials as a once-weekly injectable GLP-1/glucose-dependent insulinotropic polypeptide, or GIP, receptor dual agonist peptide that we believe offers the potential for the greatest weight loss compared to all obesity management medications currently marketed or in development with a tolerability profile that is class-like or better. We are expanding our ribupatide franchise by developing a once-daily oral tablet formulation, oral ribupatide, based on the same peptide as injectable ribupatide, to provide a convenient oral option with the potential for highly differentiated tolerability with compelling weight loss among oral treatments. Additionally, we are advancing a second oral product candidate, KAI-7535, a once-daily small molecule GLP-1 receptor agonist with the potential to improve on the clinical profile of existing oral treatments.